Nexus Clinical Research (Canada)

Institution (Company)

Homepage ROR

Also Known As

Nexus Clinical Research (Canada)

112

Publications

4.5K

Citations

Authors

Concepts

About

Nexus Clinical Research (Canada) is a company institution in St. John's, Canada known for medicine, dermatology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	32	1.8K
2	Arts	1	1	22
3	Engineering	1	1	23
4	Health Sciences	1	5	360
5	Management	1	1	22

Nexus Clinical Research (Canada)

112

Publications

4.5K

Citations

Page 1

	Year	Citations
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) Philip J. Mease, Roy Fleischmann, Atul Deodhar, Annals of the Rheumatic Diseases	2013	453
Etanercept Treatment for Children and Adolescents with Plaque Psoriasis Amy S. Paller, Elaine C. Siegfried, Richard G. Langley, New England Journal of Medicine	2008	387
Cost and health related quality of life consequences of multiple sclerosis Daniel Grima, George W. Torrance, G. Francis, Multiple Sclerosis Journal	2000	149
Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial Kim Papp, Diamant Thaçi, Danielle Marcoux, The Lancet Systemic TreatmentClinical TrialsPediatricsClinical DermatologyPharmacotherapy	2017	147
Nonlinear plasma level response to high doses of naproxen Richard Runkel, Enrico Forchielli, Hilli Sevelius, Clinical Pharmacology & Therapeutics PharmacotherapyPhysiologically-based Pharmacokinetic ModelingPharmacokineticsPharmacodynamic ModelingPharmacological Study	1974	116
Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus— and cytomegalovirus-seropositive patients Roger D. Anderson, Kay Griffy, Donald Jung, Clinical Therapeutics Treatment And PreventionNeurovirologyMedicineAntiviral Drug DevelopmentAntiviral Therapy	1995	89
Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label <scp>CADMUS</scp> Jr study Sandra Philipp, Alan Menter, Arjen Nikkels, British Journal of Dermatology	2020	77
Naproxen‐probenecid interaction Richard Runkel, Edward J. Mroszczak, M. D. Chaplin, Clinical Pharmacology & Therapeutics Healthy SubjectsNaproxen MetabolismPharmacotherapyExperimental PharmacologyPharmacokinetics	1978	72
Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts Majed Khraishi, Don MacDonald, Emmanouil Rampakakis, Clinical Rheumatology Rheumatoid DisorderRheumatologyPsoriatic Arthritis CohortsEpidemiologyMedicine	2011	72
Apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis: results from a double‐blind, placebo‐controlled, randomized study Robert Bissonnette, Richard P. Haydey, L. Rosoph, Journal of the European Academy of Dermatology and Venereology	2017	47

Page 1